Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies.
about
Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab.A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.A mathematical modelling tool for unravelling the antibody-mediated effects on CTLA-4 interactions.Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms.Characterization of CTLA4 Trafficking and Implications for Its Function
P2860
Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Remarkably similar CTLA-4 bind ...... b and tremelimumab antibodies.
@en
type
label
Remarkably similar CTLA-4 bind ...... b and tremelimumab antibodies.
@en
prefLabel
Remarkably similar CTLA-4 bind ...... b and tremelimumab antibodies.
@en
P2093
P2860
P356
P1433
P1476
Remarkably similar CTLA-4 bind ...... b and tremelimumab antibodies.
@en
P2093
Catherine W H Zhang
Jianxun Qi
Jinghua Yan
Mengnan He
Shuguang Tan
P2860
P304
67129-67139
P356
10.18632/ONCOTARGET.18004
P407
P577
2017-05-19T00:00:00Z